These findings also highlight the pressing need to estimate whether the increased cardiovascular risk observed with tofacitinib vs TNF antagonists in patients with rheumatoid arthritis also applies to other JAKi, especially selective JAK1 inhibitors and to patients with IBD. Here, TNF is linked to rheumatoid arthritis.